Anti-IL-17 Antibody Improves Hepatic Steatosis by Suppressing Interleukin-17-Related Fatty Acid Synthesis and Metabolism

Figure 1

Hepatic pathology. Liver sections stained with hematoxylin and eosin from mice. (a) Control group, (b) ALD (4W) group, (c) ALD (8W) group, (d) ALD (12W) group, and (e) Anti-IL-17 antibody treated ALD group. Original magnification ×200. Data are representative of three separate experiments.

(a)

(b)

(c)

(d)

(e)